Table S1.
Individual viral genotypes, IFNL3/4 genotypes, and demographic characteristics of HCV-infected mothers
| Subject ID | Age at delivery (y) | Estimated duration of HCV infection* (y) | Presumed route of infection | HCV genotype | IFNL3 rs12979860 | IFNL4 rs368234815 | Gravida | Pregnancy gestation at delivery (wk) | Mode of delivery | Breast-feeding duration (wk) |
| M001† | ||||||||||
| First | 27 | 12.4 | IDU | 2b | CC | TT/TT | 4 | 39.6 | Cesarean | 0 |
| Second | 30 | 15.3 | 5 | 40.1 | Cesarean | 0 | ||||
| M003† | ||||||||||
| First | 34 | 0.6 | Needle stick | 1a | CC | TT/TT | 4 | 34.0 | Vaginal | 21 |
| Second | 36 | 1.9 | 5 | 38.0 | Vaginal | 15 | ||||
| M005 | 36 | 16.6 | IDU | 1a | CC | TT/TT | 7 | 27.9 | Vaginal | 0 |
| M006 | 33 | 1.5 | IDU | 3a | CT | ΔG/TT | 4 | 36.4 | Vaginal | 0 |
| M008 | 17 | 17.3 | Vertical | 1a | CT | ΔG/TT | 1 | 36.0 | Vaginal | 11 |
| M009 | 27 | 2.5 | IDU | 1a | CT | ΔG/TT | 3 | 37.1 | Vaginal | 0 |
| M010 | 28 | 5.6 | IDU | 1a | CT | ΔG/TT | 6 | 37.3 | Vaginal | 11 |
| M013 | 26 | 0.9 | Unknown | 3a | CC | TT/TT | 5 | 34.9 | Vaginal | 0 |
| M016† | ||||||||||
| First | 24 | 4.6 | IDU | 2a | CC | TT/TT | 2 | 36.4 | Cesarean | 0 |
| Second | 26 | 6.0 | 3 | 38.3 | Cesarean | 0 | ||||
| M018 | 24 | Unknown | Unknown | 1b | CC | TT/TT | 2 | 39.0 | Cesarean | 2 |
| M019 | 29 | Unknown | Unknown | 3a | CT | ΔG/TT | 7 | 28.6 | Cesarean | 13 |
| M022 | 24 | 6.3 | IDU | 1b | CT | ΔG/TT | 3 | 40.0 | Vaginal | 0 |
| M023 | 30 | 9.6 | IDU | 2 | CT | ΔG/TT | 2 | 39.0 | Cesarean | 0 |
| M024† | ||||||||||
| First | 28 | 28.4 | Vertical | 1a | CT | ΔG/TT | 5 | 34.1 | Cesarean | 11 |
| Second | 29 | 29.3 | 6 | 36.1 | Vaginal | 7 | ||||
| M025 | 26 | 1.5 | IDU | 1a | CT | ΔG/TT | 2 | 40.1 | Vaginal | 0 |
| M026 | 27 | 1.5 | IDU | 1a | CC | TT/TT | 3 | 38.4 | Vaginal | 9 |
| M027 | 23 | 1.8 | IDU | 3a | CC | TT/TT | 3 | 38.3 | Vaginal | 0 |
| M028 | 29 | 1.9 | IDU | 2 | CT | ΔG/TT | 5 | 39.7 | Vaginal | 0 |
| M030 | 31 | 13.9 | Unknown | 1a | CT | ΔG/TT | 4 | 38.6 | Vaginal | 0 |
| M031 | 32 | 0.5 | IDU | 1a or 1c | CT | ΔG/TT | 5 | 35.0 | Vaginal | 0 |
| M033 | 26 | 0.6 | IDU | 1a | CC | TT/TT | 2 | 39.1 | Vaginal | 0 |
| M034 | 25 | 11.2 | IDU | 1b | CC | TT/TT | 3 | 39.1 | Vaginal | 17 |
| M036 | 26 | 3.2 | IDU | 2b | CC | TT/TT | 2 | 39.9 | Vaginal | 3 |
| M037 | 27 | Unknown | Unknown | 1a or 1b | CT | ΔG/TT | 5 | 38.9 | Vaginal | 0 |
| M038 | 30 | 2.8 | IDU | 3a | TT | ΔG/ΔG | 2 | 39.9 | Vaginal | 0 |
| M039 | 30 | 3.8 | IDU | 2b | CT | ΔG/TT | 4 | 40.0 | Cesarean | 0 |
| M040† | ||||||||||
| First | 24 | 3.4 | IDU | 1a | CC | TT/TT | 2 | 39.3 | Cesarean | 0 |
| Second | 25 | 4.5 | 3 | 39.1 | Cesarean | 15 | ||||
| M043 | 30 | 1.3 | IDU | 1a | TT | ΔG/ΔG | 3 | 39.0 | Vaginal | 0 |
| M048 | 28 | 1.2 | IDU | 1a | TT | ΔG/ΔG | 3 | 39.1 | Vaginal | 6 |
| M051 | 26 | 7.2 | IDU | 1a | CT | ΔG/TT | 4 | 39.1 | Vaginal | 0 |
| M062 | 25 | 1.8 | IDU | 1a | CC | TT/TT | 6 | 38.9 | Vaginal | 9 |
| M066 | 25 | 1.1 | IDU | 3a | CC | TT/TT | 4 | 39.4 | Vaginal | 0 |
| M067 | 26 | 3.7 | IDU | 1a | CT | ΔG/TT | 3 | 39.2 | Cesarean | 5 |
| M068 | 25 | 1.0 | IDU | 2b | TT | ΔG/ΔG | 2 | 39 | Cesarean | 0 |
IDU, injection drug use.
*
Assumed HCV infection acquired 6 mo after initiation of IDU or at end of reported period of IDU if duration less than 6 mo.
†
For mothers followed through two consecutive pregnancies (M001, M003, M016, M024, and M040), the second pregnancy was used for statistical analyses.